Milestone Pharmaceuticals (MIST) Expected to Release Quarterly Earnings on Wednesday

Milestone Pharmaceuticals (NASDAQ:MIST) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.20) per share and revenue of $1.00 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The business had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.82 million. On average, analysts expect Milestone Pharmaceuticals to post ($0.84) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ:MIST traded down $0.01 on Wednesday, hitting $0.75. The company had a trading volume of 155,541 shares, compared to its average volume of 1,720,448. The stock has a market cap of $93.87 million, a price-to-earnings ratio of -1.10 and a beta of 1.07. The stock has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.36. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $3.06. The company has a current ratio of 8.13, a quick ratio of 7.92 and a debt-to-equity ratio of 3.25.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Cantor Fitzgerald began coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 20th. They set an “overweight” rating and a $3.00 target price for the company. Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright restated a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Milestone Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $6.40.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders.

Milestone’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate.